NCT01562886View on ClinicalTrials.gov

The Rilpivirine Cerebrospinal-fluid (CSF) Study

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

February 28, 2013

Conditions
HIV
Interventions
DRUG

Rilpivirine

Rilpivirine 26mg

Trial Locations (1)

W2 1NY

Imperial College Healthcare NHS Trust, London

All Listed Sponsors
collaborator

Janssen-Cilag Ltd.

INDUSTRY

lead

Imperial College London

OTHER

NCT01562886 - The Rilpivirine Cerebrospinal-fluid (CSF) Study | Biotech Hunter | Biotech Hunter